Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now later-stage tilt small index

Mycoses: later-stage trial registry

1 of 8 indexed Mycoses trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #2,176 of 28,707 conditions by registered trial count.

8 US clinical trials · 1 currently recruiting · #2,176 of 28,707 conditions by registered trial count

Mycoses: 8 US clinical trials tracked, 1 recruiting.

Mycoses is the subject of 8 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 6 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 2 of these trials.

Enrollment posture brief

Registry condition mycoses

OPEN 1 | RECR 13% | LATE 6 | EARLY 1 | RANK #2176 | SPON 2

Nearest open-share peer: Acute Respiratory Infection (13% recruiting · 8 trials)

Activity, Motor75%Achalasia50%Abdominal Cancer25%Acne Scars - Mixed Atrophic 25%Mycoses (this)13%
Open-enrollment share among volume-matched conditions near Mycoses

Mycoses lists 1 open slots (13% of 8 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Mycoses on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Mycoses is recruiting below its size-band peers.

    1 of 8 indexed trials (12.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Mycoses research.

    National Cancer Institute (NCI) accounts for 2 of 8 trials (25%). 7 distinct sponsors appear on at least one study for this condition label.

  3. Typical Mycoses enrolment sits around 300 participants.

    Median target enrolment is 300 among the 8 trials that report a genuine target (sentinel values excluded). 1 of those (12.5%) plan for fewer than 100 participants.

  4. Mycoses research is mostly interventional.

    7 interventional and 1 observational studies make up this index (87.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 21Phase 35Phase 41

Open and recent trials

8 total, page 1 of 1

RECRUITING 550 participants

Prospective Data Bank Creation to Study Vaginal Conditions

Texas Tech University Health Sciences Center

NCT01829204

ACTIVE NOT RECRUITING Phase 3 602 participants

Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation

Mundipharma Research Limited

NCT04368559

COMPLETED Phase 3 450 participants

Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections

Astellas Pharma

NCT00413218

COMPLETED Phase 3 300 participants

An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infections

National Cancer Institute (NCI)

NCT00001810

COMPLETED Phase 2 207 participants

CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension

Cidara Therapeutics

NCT02734862

COMPLETED Phase 4 200 participants

Anidulafungin Versus Fluconazole for the Prevention of Fungal Infections in Liver Transplant Recipients

University of Pittsburgh

NCT00841971

COMPLETED Phase 3 100 participants

Voriconazole to Treat Fungal Infections

National Cancer Institute (NCI)

NCT00001940

COMPLETED Phase 3 20 participants

An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infections

National Institute of Allergy and Infectious Diseases (NIAID)

NCT00001757

Phase Distribution

PhaseTrial count
Phase 2 1
Phase 3 5
Phase 4 1

Named interventions

Most-linked intervention names on Mycoses records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Voriconazole Drug
4 trials
Fluconazole Drug
3 trials
Caspofungin Drug
2 trials
intravenous placebo Drug
1 trials
CD101 Drug
1 trials
oral placebo Drug
1 trials
Anidulafungin Drug
1 trials
Trimethoprim-sulfamethoxazole (TMP/SMX) Drug
1 trials

US sites by state

Facility locations filed on Mycoses trials. A trial with sites in several states counts in each.

Maryland 5 trials
Pennsylvania 4 trials
California 4 trials
New York 3 trials
Michigan 3 trials
Massachusetts 3 trials
Alabama 3 trials
Washington 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Mycoses page

8 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Mycoses condition card totals 8 registered trials; most-linked intervention Voriconazole; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.